SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:liu-86994"
 

Sökning: id:"swepub:oai:DiVA.org:liu-86994" > Targeting the EGFR ...

  • Johnston, James B.University of Manitoba,Winnipeg, MB,R3E 0V9, Canada (författare)

Targeting the EGFR pathway for cancer therapy

  • Artikel/kapitelEngelska2006

Förlag, utgivningsår, omfång ...

  • Bentham Science Publishers Ltd.2006
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-86994
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-86994URI
  • https://doi.org/10.2174/092986706779026174DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Clinical studies have shown that HER-2/Neu is over-expressed in up to one-third of patients with a variety of cancers, including B-cell acute lymphoblastic leukemia (B-ALL), breast cancer and lung cancer, and that these patients are frequently resistant to conventional chemo-therapies. Additionally, in most patients with multiple myeloma, the malignant cells over-express a number of epidermal growth factor receptors (EGFR)s and their ligands, HB-EGF and amphiregulin, thus this growth-factor family may be an important aspect in the patho-biology of this disease. These and other, related findings have provided the rationale for the targeting of the components of the EGFR signaling pathways for cancer therapy. Below we discuss various aspects of EGFR-targeted therapies mainly in hematologic malignancies, lung cancer and breast cancer. Beside novel therapeutic approaches, we also discuss specific side effects associated with the therapeutic inhibition of components of the EGFR-pathways. Alongside small inhibitors, such as Lapatinib (Tykerb, GW572016), Gefitinib (Iressa, Z131839), and Erlotinib (Tarceva, OSI-774), a significant part of the review is also dedicated to therapeutic antibodies (e.g.: Trastuzumab / Herceptin, Pertuzumab / Omnitarg / rhuMab-2C4, Cetuximab / Erbitux / IMC-C225, Panitumumab / Abenix / ABX-EGF, and also ZD6474). In addition, we summarize, both current therapy development driven by antibody-based targeting of the EGFR-dependent signaling pathways, and furthermore, we provide a background on the history and the development of therapeutic antibodies.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Navaratnam, SriUniversity of Manitoba,Winnipeg, MB,R3E 0V9, Canada (författare)
  • Pitz, Marshall W.University of Manitoba,Winnipeg, MB,R3E 0V9, Canada (författare)
  • Maniate, Jerry M.University of Manitoba,Winnipeg, MB,R3E 0V9, Canada (författare)
  • Wiechec, EmiliaManitoba Institute of Cell Biology, CancerCare Manitoba(Swepub:liu)emiwi22 (författare)
  • Baust, HeinrichUniversity of Manitoba,Winnipeg, MB,R3E 0V9, Canada (författare)
  • Gingerich, JoelUniversity of Manitoba,Winnipeg, MB,R3E 0V9, Canada (författare)
  • Skliris, Georgios P.University of Manitoba,Winnipeg, MB,R3E 0V9, Canada (författare)
  • Murphy, Leigh C.University of Manitoba,Winnipeg, MB,R3E 0V9, Canada (författare)
  • Los, Marek JanManitoba Institute of Cell Biology, Cancer Care Manitoba; Manitoba Institute of Child Health; Department of Biochemistry and Medical Genetics; Department of Human Anatomy and Cell Science, University Manitoba, Winnipeg, Canada,(Swepub:liu)marlo14 (författare)
  • University of Manitoba,Winnipeg, MB,R3E 0V9, CanadaManitoba Institute of Cell Biology, CancerCare Manitoba (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Current Medicinal Chemistry: Bentham Science Publishers Ltd.13:29, s. 3483-34920929-86731875-533X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy